Upstream Bio Investor Relations Material
Latest events
Q1 2025
6 May, 2025
Q4 2024
12 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Upstream Bio Inc
Access all reports
Upstream Bio Inc. is a U.S.-based biotechnology company focused on developing innovative therapies for inflammatory and allergic diseases. The company’s research is centered on targeting key biological pathways involved in immune response, with the goal of creating treatments that address unmet medical needs in conditions such as asthma and other chronic inflammatory disorders. Upstream Bio’s pipeline includes investigational drugs aimed at modulating immune mechanisms to improve patient outcomes and quality of life. Upstream Bio Inc. is headquartered in Waltham, Massachusetts.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
UPB
Country
🇺🇸 United States